Knowledge HQ

Clinical trial of mRNA-engineered NKG2D CAR-NK cells in metastatic colorectal cancer. NK cells were expanded from PBMCs using K562 feeder cells in G-Rex 100 vessels. Treatment was safe and showed tumor regression in local injection sites.

Patent describing the Gen 2 manufacturing process for TILs. Detailed methods include the use of G-Rex 100M and G-Rex 500M for the Rapid Expansion Protocol (REP) to shorten culture time and improve efficiency compared to the Gen 1 process.

Study on gene editing T cells to place CAR and IL-12P70 under endogenous control (TRAC, IL2Ra, PDCD1). TRACCAR T cells were expanded in G-Rex 10 devices. The engineered cells showed regulated cytokine secretion and improved anti-tumor activity.

This study develops a protocol for expanding polyclonal γδ memory T cells using artificial antigen-presenting cells in G-Rex. The method yields large numbers of potent, non-alloreactive T cells with broad anti-tumor activity. This platform supports the creation of off-the-shelf immunotherapies.

Poster describing the Iovance Gen 2 TIL manufacturing process which utilizes G-Rex for the Rapid Expansion Protocol (REP). Data shows success across melanoma, cervical, HNSCC, sarcoma, and lung cancers with high viability and T-cell purity.

Clinical data on Lifileucel (LN-144) for metastatic melanoma. The manufacturing process involves a 22-day protocol using G-Rex. Shows 40.5% ORR in primary refractory patients.

NKG2D.zeta-NK cells were generated and expanded in G-Rex devices. These cells eliminated myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, enhancing the infiltration and efficacy of GD2.CAR-T cells in neuroblastoma models.

Mycobacteria-specific T cells (MSTs) were expanded from healthy donors using peptide pools and G-Rex 10. The protocol yielded polyfunctional CD4+ T cells. MSTs were largely absent in patients with primary immunodeficiencies.

Describes a 9-day protocol for generating CAR-T cells from rhesus macaque PBMCs. G-Rex 6-well plates were used for the expansion phase (days 5-9). The method produced high numbers of viable cells with a central memory phenotype suitable for infusion.

Report on a patient with metastatic colorectal cancer treated with TILs targeting a p53 mutation. TILs were screened and expanded using G-Rex 100. Although specific T-cells were identified, clinical response was limited due to loss of HLA heterozygosity in the tumor.

A Phase II study evaluating low-dose IL-2 with TILs for metastatic melanoma. 12 patients treated with non-myeloablative chemotherapy and TILs expanded in G-Rex100. Two partial responses and one unconfirmed PR were observed. Low-dose IL-2 was feasible but resulted in lower response rates compared to high-dose regimens.

A review of CAR T-cell process development challenges. It highlights G-Rex as an alternative to bags, capable of supporting high T-cell numbers (~20x10^9) and adaptable to automated harvesting systems.